C.V.-C. receives funding from the National Institute on Aging (NIA) K99AG073452. M.M.M. receives funding from the National Institute on Aging (RF1 AG055151, U54 AG044170, RF1 AG077386; RF1 AG079397). C.U.-M. is funded by Janssen R&D, Gates Ventures, Takeda and Merck, and received project grants from the RoseTrees Foundation Trust, Alzheimer Research UK and the British Society for Neuroendocrinology.